Abstract:In order to explore the effect of compound Aucklandia lappa health wine on rats (Rattus norvegicus) with spleen deficiency, SPF SD rats were selected and the rat model of spleen deficiency was constructed by subcutaneous injection of reserpine combined with irregular feeding. SPF SD rats were selected, subcutaneously injected with reserpine combined with irregular feeding to replicate the spleen deficiency model. After successful modeling, 6 treatment groups were set up, each containing 10 rats, with half male and half female, in which: the normal group (N group) maintained the normal feeding mode, and the model group (T0 group) maintained the state of splenic deficiency, and none of them was treated with medication; the mosapride group (TM group) was administered with 0.01 g of mosapride citrate per 1 kg of body mass. The dosages of low, medium, and high dose groups (T1, T2, and T3 groups) were 10.0, 5.0, and 2.5 mL of compound A. lappa health wine per 1 kg body mass, respectively (the drug content was equivalent to the mass concentration of raw medicinal materials of 3.00 g·mL -1). After 14 days of continuous administration, blood samples were collected from rats and the relevant blood indexes were measured. The results showed that: 1) the rats in the T0 group had still obvious symptoms such as depression, clustering, arched back, withered fur and lethargy; the spleen deficiency symptoms of T1, T2, T3, and TM groups of rats were alleviated, and the growth rate of body mass and food utilization rate increased compared with those in the T0 group. 2) After drug treatment, the platelet count in the blood of splenic asthenia rats was increased, and the white blood cell count and total protein mass concentration were not significantly different from those of normal rats; however, hemoglobin mass concentration and erythrocyte count were not restored. 3) Serum D-xylose mass concentration in group N was significantly higher than that in group T0 (p<0.05), and there was no significantly different between group T3 and group N, but there was significantly different between group T3 and group T0 (p<0.05).The mass concentration of serum immunoglobulin G in group N was significantly higher than that in group T0 (p<0.05), but there was no significantly different between the 4 drug treatment groups and group N. Compared with T0 group, the serum gastrin in N group and T3 group was significantly increased (p<0.01). There was no significantly different in this index among males in N group and T3 group, but there was significantly different among females in N group and T3 group (p<0.05). Serum gastrin concentration in group N was significantly higher than that in the other 5 groups (p<0.05), and the serum gastrin concentration in groups TM and T3 was also significantly higher than that in group T0 (p<0.05). The concentration of serum vasoactive intestinal peptide was significantly different between group N and group T0 (p<0.01); among male individuals, the concentration of serum vasoactive intestinal peptide in TM and T3 groups was significantly higher than that in T0 group (p<0.05), but there was no statistically significant difference in this index compared with that in N group; among female individuals, the serum vasoactive intestinal peptide concentration in T3 group was significantly higher than that in T0 group (p<0.01), and the serum vasoactive intestinal peptide concentration in T3 group was significantly lower than that in N group (p<0.05). There was a significantly different in the concentration of amylase between the female rats of group N and T0 (p<0.05), but there was no significantly different in this index between the male rats of group N and T0, and there was no significantly different in this indicator between the T2 group, T3 group, and TM group compared to the N and T0 groups. From the above results, it can be concluded that compound A. lappa health wine can enhance the gastrointestinal motility of rats with spleen deficiency, promote digestion and absorption, enhance immunity, and ultimately promote the recovery of rats with spleen deficiency.